Pantoprazole Sodium
PANTOPRAZOLE SODIUM- pantoprazole sodium tablet, delayed release
RxChange Co.
1 INDICATIONS AND USAGE
Pantoprazole sodium delayed-release tablets USP are indicated for:
1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD)
Pantoprazole sodium delayed-release tablets USP are indicated in adults for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets USP may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established.
1.2 Maintenance of Healing of Erosive Esophagitis
Pantoprazole sodium delayed-release tablets USP are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD. Controlled studies did not extend beyond 12 months.
1.3 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
Pantoprazole sodium delayed-release tablets USP are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosing Schedule
Pantoprazole sodium is supplied as delayed-release tablets. The recommended dosages are outlined in Table 1.
| ||
Indication | Dose | Frequency |
Short-Term Treatment of Erosive Esophagitis Associated With GERD | ||
Adults | 40 mg | Once daily for up to 8 weeks * |
Children (5 Years and Older) | ||
≥ 15 kg to < 40 kg | 20 mg | Once Daily for up to 8 wks |
≥ 40 kg | 40 mg | |
Maintenance of Healing of Erosive Esophagitis | ||
Adults | 40 mg | Once daily |
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome | ||
Adults | 40 mg | Twice daily † |
2.2 Administration Instructions
Directions for method of administration are presented in Table 2.
| ||
Formulation | Route | Instructions * |
Delayed-Release Tablets | Oral | Swallowed whole, with or without food |
Pantoprazole Sodium Delayed-Release Tablets
Pantoprazole sodium delayed-release tablets should be swallowed whole, with or without food in the stomach. If patients are unable to swallow a 40 mg tablet, two 20 mg tablets may be taken. Concomitant administration of antacids does not affect the absorption of pantoprazole sodium delayed-release tablets.
3 DOSAGE FORMS AND STRENGTHS
Delayed-Release Tablets:
- 20 mg: Yellow, oval shaped, unscored tablets imprinted with black ink on one side of the tablet “93/11” and plain on the other side.
- 40 mg: Yellow, oval shaped, unscored tablets imprinted with black ink on one side of the tablet “93/12” and plain on the other side.
4 CONTRAINDICATIONS
Pantoprazole sodium delayed-release tablets are contraindicated in patients with known hypersensitivity to any component of the formulation [see Description (11) ] or any substituted benzimidazole.
5 WARNINGS AND PRECAUTIONS
5.1 Concurrent Gastric Malignancy
Symptomatic response to therapy with pantoprazole does not preclude the presence of gastric malignancy.
5.2 Atrophic Gastritis
Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with pantoprazole, particularly in patients who were H. pylori positive.
5.3 Cyanocobalamin (Vitamin B-12) Deficiency
Generally, daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (Vitamin B-12) caused by hypo- or achlorhydria. Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature. This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed.
5.4 Clostridium difficile Associated Diarrhea
Published observational studies suggest that PPI therapy like pantoprazole may be associated with an increased risk of Clostridium difficile associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve [see Adverse Reactions (6.2) ].
Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.